NeOnc Technologies Holdings, Inc. Common Stock Total Liabilities
NeOnc Technologies Holdings, Inc. Common Stock total liabilities. Based on the latest financial reports, NeOnc Technologies Holdings, Inc. Common Stock (NTHI) has total liabilities worth $23.76 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See NeOnc Technologies Holdings, Inc. Common liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of NeOnc Technologies Holdings, Inc. Common Stock (2021–2025)
Total liabilities of NeOnc Technologies Holdings, Inc. Common Stock from 2021 to 2025. This chart illustrates how NeOnc Technologies Holdings, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
NeOnc Technologies Holdings, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of NeOnc Technologies Holdings, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Industri Dan Perdagangan Bintraco Dharma Tbk PT
JK:CARS
|
Indonesia | Rp2.10 Trillion |
|
Hwaseung Corporation Co Ltd
KO:013520
|
Korea | ₩915.60 Billion |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$39.34 Million |
|
Laster Tech Corp Ltd
TW:3346
|
Taiwan | NT$6.30 Billion |
|
Centrale d'Achat Française pour l'Outre-Mer Société Anonyme
PA:CAFO
|
France | €250.52 Million |
|
Shalimar Paints Limited
NSE:SHALPAINTS
|
India | Rs4.03 Billion |
|
Country View Bhd
KLSE:5049
|
Malaysia | RM166.76 Million |
|
Regis Corporation Common Stock
NASDAQ:RGS
|
USA | $353.41 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down NeOnc Technologies Holdings, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NeOnc Technologies Holdings, Inc. Common total assets.
Liquidity & Leverage Metrics
NeOnc Technologies Holdings, Inc. Common Stock Total Liabilities Ratios Explained
NeOnc Technologies Holdings, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NeOnc Technologies Holdings, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NeOnc Technologies Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of NeOnc Technologies Holdings, Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.33 Million | +127.87% |
| 2024-12-31 | $8.92 Million | -41.51% |
| 2023-12-31 | $15.25 Million | +562.02% |
| 2022-12-31 | $2.30 Million | -13.01% |
| 2021-12-31 | $2.65 Million | -- |
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical… Read more